This is a retrospective medical records review of 50 patients (54 eyes) with retinoblastoma (RB), who received I-125 episcleral plaque brachytherapy (EPBRT) prior to (primary) or following chemoreduction (delayed) alone and in combination with non-irradiative focal therapy. Fifty-six plaques were used between 1986 to 2010, with a median follow-up of 8.3 years. The median time from diagnosis to plaque placement was 12.7 months. Treatment failure was defined as the need for subsequent external beam radiation (EBRT) and / or enucleation. Cumulative incidences (CI) and 95% CI of treatment failure and enucleation following EPBRT at five years was 37% and 42.2% respectively. The absence of prior diode or green laser therapy was predictive of increased risk for treatment failure (p=0.02 and 0.03). The authors concluded that the use of any focal treatment was not predictive of time to treatment failure (p=0.33) or the need for EBRT to achieve successful salvage. International Classification C or D was predictive of decreased time to enucleation (p=0.004).

Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy (EPBRT) in retinoblastoma (RB).
Lucas Jl, McGee R, Billups CA, et al.
Share This
Jonathan Chan

Royal Hallamshire Hospital, Sheffield, UK.

View Full Profile